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difference between the mortality in the treatment (16.7%) and
control (10%) arms. In the control group, 2 patients died. There
was no significant change in functional class or left ventricular
function in this group.
In summary, 24 patients underwent intracoronary stem cell
injection with coronary sinus blockage. Four patients died during
the 6-month follow-up. Overall EF showed a small but significant
improvement of 5.4%. There was a decrease in end-systolic
volumes, but no change in end-diastolic volumes. Endomyocardial
biopsy done at 3 months showed no significant change in the
number of myocytes or capillaries, but the ratio of capillaries to
myocytes showed an insignificant increase. There were soft data to
suggest cell proliferation (binucleate cells and Ki 67 positivity).
This is the first study of stem cell therapy in dilated nonischemic
cardiomyopathy. Over a 6-month period, there was a small albeit
significant improvement in ventricular function. Previous clinical
studies have also shown a small degree of change in ventricular
function of a similar magnitude (1,2). Laboratory experiments in
nonischemic dilated cardiomyopathy (3) have previously suggested
that benefit from stem cell therapy in this group comes mainly
from a decrease in fibrosis and an increase in vascularity, but no
evidence has been found supporting transdifferentiation of stem
cells to myocytes. Our data also suggest that the benefit of stem cell
therapy could be a paracrine effect with changes in vascularity, perhaps
stimulation of cell proliferation, or by some still-unexplored mecha-
nism. We did not find any evidence of transdifferentiation.
In this study we wish to highlight a number of issues. It is the
first study to show the benefit of stem cells in nonischemic dilated
cardiomyopathy, and the first study that uses coronary sinus
occlusion to increase cell contact time. It is also the first study in
which we have endomyocardial biopsies performed after stem cell
therapy.
It provides a stimulus for exploring the benefits of stem cell
therapy in nonischemic dilated cardiomyopathy. A double-blind
study is being planned to further explore the benefit seen in this
preliminary study. The small magnitude of benefit could perhaps
be because all patients in this study were in very late stages of their
cardiomyopathy, and we probably need to consider stem cell
therapy at a much earlier stage. Endomyocardial biopsy, performed
for the first time in stem cell therapy, shows no evidence of
transdifferentiation of stem cells to myocytes but provides soft data
pointing to a possible paracrine effect.
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Are Familial Mediterranean Fever (FMF) Patients at Increased Risk for Atherosclerosis?
Impaired Endothelial Function and Increased Intima Media Thickness Are Found in FMF
To the Editor: Familial Mediterranean fever (FMF) is an auto-
inflammatory disease characterized by periodic attacks of fever and
serositis caused by mutations in FMF gene (MEFV). Although
FMF patients are symptom free between the attacks, subclinical
inflammation continues during the attack-free period (1). Patients
with inflammatory diseases, such as those with systemic lupus
erythematosus and rheumatoid arthritis, are now considered to
have an increased risk of atherosclerotic cardiovascular complica-
tions. Intima media thickness (IMT) of carotid arteries and
endothelial dysfunction are used to define the preclinical athero-
sclerosis (2). We attempted to determine whether FMF patients
have an increased risk of atherosclerosis by assessing endothelium-
dependent flow-mediated dilation (FMD) of brachial artery and
IMT of carotid arteries. We also investigated the association
between these parameters and inflammatory markers.
We studied 43 FMF patients and 29 healthy control subjects.
All FMF patients enrolled in the study fulfilled the clinical criteria
for FMF (3). Patients with diabetes mellitus, hypertension, ath-
erosclerotic vascular disease, malignancy, amyloidosis, active infec-
tious disease, pregnancy, or other inflammatory diseases were
excluded. All subjects had a complete history and physical exam-
ination. Clinical and laboratory assessment of FMF patients were
performed during an attack-free period. The FMF patients unre-
sponsive to colchicine therapy have been previously defined (4).
Erythrocyte sedimentation rate (ESR) and fibrinogen were
measured. Serum glucose and serum lipids were determined by
using an autoanalyzer. Serum amyloid A (SAA) was determined by
a commercial micro– enzyme-linked immunosorbent assay
method, and high-sensitivity C-reactive protein (hs-CRP) was
determined by immunonephelometry. Genetic analysis data of
FMF patients were obtained from hospital file records.
Endothelial function was assessed by FMD from the brachial
artery, and IMT of carotid arteries was measured as previously
described (5,6). The maximum IMT (the highest value of the 6
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measurements) was used in statistical analysis. The IMT was
considered normal when the intima-media complex was 0.9 mm
according to the current sonographic criteria. Maximum IMT
values of 0.9 to 1.3 mm were considered indicative of thickened
intima, and the values 1.3 mm indicated an atherosclerotic
plaque (6).
The SPSS version 11.0 software (SPSS Inc., Chicago, Illinois)
was used for data analysis. Categorical and numeric variables were
tested by chi-square or Fisher exact tests and Student t test or
Mann-Whitney U test, respectively. Correlation was tested with
Spearman or Pearson correlation coefficients. Analysis of covari-
ance was used to adjust for high-density lipoprotein (HDL) or
total cholesterol levels, while checking for the effect of FMF on
FMD or maximum IMT. A significance level was set at p  0.05.
General characteristics of the patients with FMF and control
subjects were similar. All FMF patients were on colchicine
treatment. Five patients (12%) were considered colchicine nonre-
sponders. None of the patients had proteinuria. Data of genetic
analysis were available in 28 patients. The most frequent 3
mutations were M694V (53.6%), V726A (14.9%), and M680I
(14.9%). Among 28 patients, 9 patients (32%) had homozygote
mutations, 13 patients (46%) had compound heterozygote muta-
tions, 2 patients (7%) had heterozygote mutations, and 1 patient
(4%) had complex allele with M694V/M694V-E148Q.
Total cholesterol (164  34 mg/dl vs. 188  46 mg/dl, p 
0.02) and HDL cholesterol (49  14 mg/dl vs. 57  14 mg/dl, p
 0.03) were significantly lower, ESR (median: 7 mm/h [range: 2
to 66 mm/h] vs. median: 5 mm/h [range: 1 to 4 mm/h], p 
0.003), fibrinogen (324.64  77.93 mg/dl vs. 283.80  57.10
mg/dl, p  0.02), and hs-CRP (3 mg/l [0.2 to 30.4 mg/l] vs. 0.7
mg/l [0.2 to 3.6 mg/l], p  0.001) were significantly higher in the
FMF group. Serum amyloid A (21.82 U/l [4.25 to 300 U/l] vs.
10.33 U/l [6.00 to 89.10 U/l], p  0.004), FMD (5.7  2.4% vs.
10.8  1.9%, p  0.001), maximum IMT (0.79  0.18 mm vs.
0.61  0.11 mm, p  0.001), mean IMT (0.62  0.08 mm vs.
0.53  0.07 mm, p  0.001) of right carotid arteries, and mean
IMT (0.61 0.07 mm vs. 0.53 0.07 mm, p 0.001) of the left
carotid arteries were also significantly higher in the FMF group.
The FMD impairment was more prominent in M694V homozy-
gote patients compared with those without this mutation (4.3 
1.5% vs. 6.5  2.2%, p  0.005) (Fig. 1). There was a positive
correlation between the maximum IMT of carotid arteries and age
(r  0.29; p  0.014). Atherosclerotic plaques were detected in 2
of the FMF patients and none of the control group. Using
covariance analysis, after adjustment by HDL or total cholesterol
separately, the presence of FMF was shown to be a significant risk
factor for both increased IMT and decreased FMD (p  0.001 for
all).
Neither FMD nor maximum IMT of carotid arteries were
different between colchicine responder and nonresponder patient
groups (p  NS for all). Both FMD of brachial artery and IMT of
carotid arteries did not correlate with disease duration, age of
symptom onset, duration of colchicine treatment, or current
colchicine dosage in FMF patients (p  NS for all).
In this study we found that endothelium-dependent FMD was
reduced and IMT of the carotid arteries was increased in FMF
patients compared with healthy controls. Acute-phase reactant
levels were higher in FMF patients as expected. We suggest that
ongoing low-grade inflammation may be the cause of the thick-
ened IMT of the carotid arteries and endothelial dysfunction
reflected by reduced FMD in FMF patients.
Langevitz et al. (7) found that ischemic heart disease prevalence
was 15.5% in FMF patients, which is lower than expected, but our
results suggest that there may still be an increased risk for
atherosclerotic vascular complications in FMF patients, as in other
inflammatory diseases.
Serum lipid changes in FMF patients resemble those in chronic
inflammatory diseases, so we think that these changes may be
another feature of the ongoing inflammation (8). Other than the
effect of FMF disease itself, a decreased HDL cholesterol level
was not found to introduce additional risk for the reduced FMD
or thickened maximum IMT of carotid arteries in this study.
Although the IMTs of carotid arteries were higher in FMF
patients, there were only 2 atherosclerotic plaques detected in
FMF patients. These results may be attributable to our relatively
young patient population. On the other hand, this is a cross-
sectional study with a limited number of subjects; therefore, our
results should be assessed cautiously. Our control subjects were
enrolled from the hospital staff, which could also be thought to be
a potential bias.
The MEFV mutations were found to be associated with the
severity of inflammatory diseases. Homozygote M694V mutation
is associated with a more severe disease course and risk for
developing amyloidosis in FMF. The carrier rate of MEFV
mutations reaches about 20% to 30% of the population in certain
ethnic groups. Ongoing low-grade inflammation was shown not
only in FMF patients but also in carriers of MEFV mutations (1).
Further assessment of the effect of these mutations on the
atherosclerotic process will provide more a accurate risk stratifica-
tion for those who have these mutations. The role of impaired
endothelial function and IMT of carotid arteries in detecting
amyloidosis should also be evaluated in patients with FMF.
Further investigations in larger samples are needed to establish the
relationship between FMF and atherosclerosis.
Figure 1. Comparison of flow-mediated dilation (FMD) between M694V
homozygote FMF patients and FMF patients with other mutations. FMF
 familial Mediterranean fever.
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Letters to the Editor
Physiologic Timing
for Objective Checking of
Instantaneous Maximal Aortic Stenotic Area
Feuchtner et al. (1) recently proposed a new and successful method
for imaging and evaluating aortic valve area (AVA) in aortic
stenosis (AS) using a 16-row multislice computed tomography
MSCT scanner. The investigators reasonably indicated that
MSCT was not a primary diagnosis imaging technique, recalling
the feasibility and cost-effectiveness of the usual echo-Doppler
techniques in clinical practice. I agree with these general consid-
erations and appreciated the study. Some comments are needed
about the methodology they used to acquire images.
On the one hand, an obvious discrepancy exists between the
described method in their study, assuming an approximate value of
50 ms for isovolumetric contraction (IC), and the diagram shown
in their Figure 1 (top row). This 50-ms time interval is stated to be
subtracted from the duration of the cardiac cycle for the recon-
struction of the first image. Everyone may agree with the 50-ms
approximation for IC. Figure 1, however, shows that the so-called
IC starts with QRS of the electrocardiogram (ECG) and covers
the full duration of the QRS complex. This illustration raises a
didactical issue: the total QRS duration normally ranges about
120 ms and, thus; widely exceeds 50 ms. The QRS onset is the
initial marker of the pre-ejection period, of which IC is only a
component, succeeding to the electromechanical delay, and ending
with the opening of the aortic valve, marker of ejection onset. The
IC has a physiologic interest because it corresponds to the rapid
rise of left ventricular pressure, which requires mitral valve closure
and lags behind QRS onset.
In brief, if only 50 ms were subtracted, the latest part of
pre-ejection, which is precisely IC, would be integrated into the
duration of the cardiac cycle. This may be of limited consequence
on final imaging measurements, but, regretably, it makes Figure 1
erroneous and confuses the reader.
On the other hand, MSCT enables one to directly image
instantaneous AVA, which varies along systole. The assumption
that maximal AVA coincides with the maximal pressure drop has
been substantiated by studies using the continuity equation over
systole (2). No significant difference was reported either between
timings of maximal Doppler jet flow AVA and maximal pressure
gradient (3). Rather than studying reconstructed images generated
during the entire mid-late systole every 50 ms in order to identify
the phase of maximal AVA (1), a less empiric way of selecting
maximal AVA would consist of triggering the image at peak
velocity of the stenotic jet recorded by continuous-wave Doppler.
Peak velocity has a reproducible timing (3). The reliable ultrasound
assessment of AVA it provides could easily be applied to other
imaging modalities. Advantages of this specific timing are 3-fold:
1) it relies on a physiologic substrate; 2) it enables comparison
between laboratories; and 3) it facilitates follow-up of patients by
relying on an objective landmark.
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